PH12022550192A1 - Alcohol derivatives as kv7 potassium channel openers - Google Patents

Alcohol derivatives as kv7 potassium channel openers

Info

Publication number
PH12022550192A1
PH12022550192A1 PH1/2022/550192A PH12022550192A PH12022550192A1 PH 12022550192 A1 PH12022550192 A1 PH 12022550192A1 PH 12022550192 A PH12022550192 A PH 12022550192A PH 12022550192 A1 PH12022550192 A1 PH 12022550192A1
Authority
PH
Philippines
Prior art keywords
potassium channel
alcohol derivatives
channel openers
compounds
potassium channels
Prior art date
Application number
PH1/2022/550192A
Other languages
English (en)
Inventor
Shu Hui Chen
Debasis Das
Jian Hong
Krestian Larsen
Mario Rottlã„Nder
Anette Graven Sams
Xiaofang Wang
Original Assignee
H Lundbeck As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by H Lundbeck As filed Critical H Lundbeck As
Publication of PH12022550192A1 publication Critical patent/PH12022550192A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/08Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atom of at least one of the carboxamide groups bound to an acyclic carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/26Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being saturated and containing rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00Carboxylic acid nitriles
    • C07C255/01Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/42Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms
    • C07C255/44Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms at least one of the singly-bound nitrogen atoms being acylated
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/02Systems containing only non-condensed rings with a three-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/04Systems containing only non-condensed rings with a four-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/06Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
PH1/2022/550192A 2019-08-02 2020-07-30 Alcohol derivatives as kv7 potassium channel openers PH12022550192A1 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP19189750 2019-08-02
CN201910734123 2019-08-09
EP19191887 2019-08-15
PCT/EP2020/071520 WO2021023617A1 (en) 2019-08-02 2020-07-30 Alcohol derivatives as kv7 potassium channel openers

Publications (1)

Publication Number Publication Date
PH12022550192A1 true PH12022550192A1 (en) 2022-11-21

Family

ID=71894829

Family Applications (1)

Application Number Title Priority Date Filing Date
PH1/2022/550192A PH12022550192A1 (en) 2019-08-02 2020-07-30 Alcohol derivatives as kv7 potassium channel openers

Country Status (26)

Country Link
EP (2) EP4007634B1 (https=)
JP (2) JP7720829B2 (https=)
CN (1) CN114206830B (https=)
AU (1) AU2020325517B2 (https=)
BR (1) BR112021006324A2 (https=)
CA (1) CA3148719A1 (https=)
CL (1) CL2022000221A1 (https=)
CO (1) CO2022000080A2 (https=)
CR (1) CR20220028A (https=)
DO (1) DOP2022000026A (https=)
EC (1) ECSP22008993A (https=)
ES (1) ES2989376T3 (https=)
GE (2) GEAP202415862A (https=)
HR (1) HRP20241444T1 (https=)
HU (1) HUE069310T2 (https=)
IL (1) IL290193B2 (https=)
JO (1) JOP20220017A1 (https=)
MA (1) MA56708B1 (https=)
MX (1) MX2022001063A (https=)
PE (1) PE20220345A1 (https=)
PH (1) PH12022550192A1 (https=)
PL (1) PL4007634T3 (https=)
RS (1) RS66130B1 (https=)
SM (1) SMT202400445T1 (https=)
WO (1) WO2021023617A1 (https=)
ZA (1) ZA202109598B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS66130B1 (sr) * 2019-08-02 2024-11-29 H Lundbeck As Derivati alkohola kao otvarači kv7 kalijumovih kanala
IL325387A (en) * 2023-06-27 2026-02-01 Saniona As KV7 modulators

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001092526A1 (en) 2000-05-26 2001-12-06 Bristol-Myers Squibb Company Human kcnq5 potassium channel, methods and compositions thereof
WO2001096540A2 (en) 2000-06-11 2001-12-20 Dupont Pharmaceuticals Company Hepatitis c protease exosite for inhibitor design
US7091202B2 (en) * 2004-09-15 2006-08-15 Bristol-Myers Squibb Company 4-arylspirocycloalkyl-2-aminopyrimidine carboxamide KCNQ potassium channel modulators
TWI453013B (zh) 2006-02-07 2014-09-21 Lundbeck & Co As H N-(2,4-二甲基-6-嗎啉-4-基-吡啶-3-基〉3,3-二甲基-丁醯胺之用途以及包含該化合物之醫藥品
WO2007104717A1 (en) * 2006-03-15 2007-09-20 Neurosearch A/S Quinazolinones and their use as potassium channels activators
AR070513A1 (es) 2007-08-01 2010-04-14 Lundbeck & Co As H Uso de abridores de canales de potasio kcnq para reducir los sintomas o tratar desordenes o afecciones en las cuales se encuentra anulado el sis-tema dopaminergico como por ejemplo esquizofrenia y trastorno depresivo mayor
TW201024286A (en) * 2008-11-27 2010-07-01 Neurosearch As Novel compounds
HK1216095A1 (zh) * 2012-12-10 2016-10-14 H. Lundbeck A/S 烟碱乙酰胆碱受体的新的正向别构调节剂
WO2014145852A2 (en) * 2013-03-15 2014-09-18 Knopp Biosciences Llc Imidazo(4,5-b) pyridin-2-yl amides as kv7 channel activators
SMT202300362T1 (it) * 2014-09-12 2023-11-13 Biohaven Therapeutics Ltd Benzoimidazol-1,2-il-ammidi come attivatori di canale kv7
JP2017095366A (ja) 2015-11-18 2017-06-01 持田製薬株式会社 新規ビアリールアミド誘導体
CN105663136A (zh) * 2016-01-15 2016-06-15 河北中医学院 法舒地尔作为制备选择性Kv7离子通道激活剂药物的应用
EP4241843B1 (en) * 2018-02-20 2025-05-21 H. Lundbeck A/S Alcohol derivatives as kv7 potassium channel openers
RS66130B1 (sr) * 2019-08-02 2024-11-29 H Lundbeck As Derivati alkohola kao otvarači kv7 kalijumovih kanala
CN114206328B (zh) * 2019-08-02 2024-09-17 H.隆德贝克有限公司 用于在癫痫或癫痫发作中使用的作为Kv7钾通道开放剂的醇衍生物

Also Published As

Publication number Publication date
CA3148719A1 (en) 2021-02-11
JP7720829B2 (ja) 2025-08-08
JP2025160211A (ja) 2025-10-22
RS66130B1 (sr) 2024-11-29
KR20220041084A (ko) 2022-03-31
JOP20220017A1 (ar) 2023-01-30
GEAP202415862A (en) 2024-01-25
ES2989376T3 (es) 2024-11-26
CO2022000080A2 (es) 2022-01-17
SMT202400445T1 (it) 2024-11-15
HRP20241444T1 (hr) 2024-12-20
CR20220028A (es) 2022-03-02
DOP2022000026A (es) 2022-03-31
CN114206830B (zh) 2024-07-30
GEP20247629B (en) 2024-06-10
ECSP22008993A (es) 2022-03-31
MA56708B1 (fr) 2024-12-31
IL290193B1 (en) 2024-08-01
PE20220345A1 (es) 2022-03-14
IL290193A (en) 2022-03-01
IL290193B2 (en) 2024-12-01
ZA202109598B (en) 2024-04-24
WO2021023617A1 (en) 2021-02-11
EP4007634B1 (en) 2024-10-02
MX2022001063A (es) 2022-02-14
EP4461725A3 (en) 2025-01-15
EP4461725A2 (en) 2024-11-13
PL4007634T3 (pl) 2024-11-25
AU2020325517B2 (en) 2025-08-28
AU2020325517A1 (en) 2022-02-24
HUE069310T2 (hu) 2025-02-28
CN114206830A (zh) 2022-03-18
BR112021006324A2 (pt) 2022-02-15
EP4007634C0 (en) 2024-10-02
JP2022543203A (ja) 2022-10-11
CL2022000221A1 (es) 2022-10-07
EP4007634A1 (en) 2022-06-08

Similar Documents

Publication Publication Date Title
EP4241843A3 (en) Alcohol derivatives as kv7 potassium channel openers
WO2020160193A3 (en) Compounds and uses thereof
MX2022001310A (es) Compuesto de fenil-2-hidroxi-acetilamino-2-metil-fenilo.
JOP20210091A1 (ar) مشتقات أريل سلفونيل بيرول كربوكساميد على هيئة عوامل تنشيط قناة بوتاسيوم Kv3
EA201790806A1 (ru) Иммунорегулирующие средства
CR20220207A (es) Compuestos terapéuticos y métodos de uso
NZ724878A (en) Compounds and compositions as toll-like receptor 7 agonists
HK1220442A1 (zh) Ido抑制剂
MX2023004869A (es) Anticuerpos contra sars-cov-2 y usos de los mismos.
WO2019226213A3 (en) AMINOPYRAZINE DIOL COMPOUNDS AS PI3K-y INHIBITORS
MX2023001296A (es) Composiciones y metodos para tratar enfermedades y trastornos.
EP4252755A3 (en) Therapeutic compounds
MX2018000515A (es) Compuestos fluorados de cbd, composiciones y usos de los mismos.
MX2021006515A (es) Composiciones de methylobacterium para mejorar el rendimiento del maíz.
WO2019078968A3 (en) Cyclic compounds as immunomodulating agents
AU2018279184A1 (en) Anti-TrkB antibodies
ZA202109598B (en) Alcohol derivatives as kv7 potassium channel openers
WO2019241644A8 (en) Novel small molecule anticancer agents, combinations and uses thereof
MX2022001805A (es) Formulaciones de anticuerpos anti-esclerostina.
PH12019500801A1 (en) Structures and mechanism for the design of highly potent glucocorticoids
PH12021552042A1 (en) Novel potassium channel inhibitors
MX2023003306A (es) Inhibidores del canal de potasio novedosos.
GB2553686A (en) Ethynylxanthines, preparation and use as calcium ion channel modulators
EA202091327A1 (ru) Макроциклические соединения для лечения заболеваний
EA202091124A1 (ru) Соединения для лечения нарушений со стороны нервно-мышечной системы